Buprenorphine in Neonatal Abstinence Syndrome
- PMID: 29105752
- PMCID: PMC5739935
- DOI: 10.1002/cpt.930
Buprenorphine in Neonatal Abstinence Syndrome
Abstract
Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long-acting opioid with therapeutic use in medication-assisted treatment of opioid dependency in adults and adolescents. Emerging data from clinical trials and treatment cohorts demonstrate the efficacy and safety of sublingual buprenorphine for those infants with NAS who require pharmacologic treatment. Pharmacometric modeling will assist in defining the exposure-response relationships and facilitate dose optimization.
© 2017 American Society for Clinical Pharmacology and Therapeutics.
Conflict of interest statement
Dr. Kraft has served as an unpaid consultant to Chiesi Farmaceutici S.p.A.
Figures
References
-
- Goasdoue K, Miller SM, Colditz PB, Bjorkman ST. Review: the blood-brain barrier; protecting the developing fetal brain. Placenta. 2017;54:111–116. - PubMed
-
- Bauer CR, et al. Acute neonatal effects of cocaine exposure during pregnancy. Arch. Pediatr. Adolesc. Med. 2005;159:824–834. - PubMed
-
- Food and Drug Administration. [Accessed 6 September 2017];FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. 2011 < https://www.fda.gov/Drugs/DrugSafety/ucm243903.htm>.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
